Acute bone damage through liver-bone axis induced by thioacetamide in rats.
Bone damage
Hepatic fibrosis
Rat model
Thioacetamide
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
07 05 2022
07 05 2022
Historique:
received:
03
07
2020
accepted:
25
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Thioacetamide (TAA) is used in various fields, such as synthetic drugs, organic chemical synthesis, and materials chemistry. TAA is mainly used to establish animal liver injury models and other organ damage models to explore their mechanisms for helping patients with liver disease. Liver damage can lead to abnormal expression of some enzymes in the serum, so we detected the appropriate enzyme levels in the serum of SD rats to verify the damage of TAA to the liver. More importantly, TAA caused bone damage is barely understood. Therefore, our research aims to establish a rat model reflecting the acute bone damage injury caused by TAA. The SD rats were intraperitoneally injected with normal saline (0.9%) or TAA (200 mg/kg, 400 mg/kg) for 1 month (once the other day). After the last intraperitoneal injection, serum samples from rats were used for biochemical tests. Masson staining is used to detect liver damage, and micro-CT is used to detect the changes in bone. Moreover, the three-point bending experiment was used to detect the force range of the hind limbs of SD rats. Compared with the control group, after the intraperitoneal injection of TAA, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), total bile acid (TBA), alkaline phosphatase (ALP), carbamide (UREA) and creatinine (CREA) rose sharply, while the levels of serum content of total protein (TP), lactate dehydrogenase (LDH), calcium (Ca) and phosphorus (P) were severely reduced. After TAA administration, collagen fibers were deposited and liver fibrosis was obvious. Micro-CT results showed that the bone surface, tissue surface, bone volume, and tissue volume of rats with an intraperitoneal injection of TAA were significantly reduced. In addition, the bones of rats with an intraperitoneal injection of TAA can resist less pressure and are prone to fractures. TAA can cause liver damage in SD rats, which is explained by the changes in serum biochemical indicators and the deposition of liver collagen. More importantly, TAA can reduce bone mineral density and increase the separation of bone trabeculae in SD rats, and finally lead to bone injury. This suggests that TAA may become an ideal model to investigate abnormal bone metabolism after liver injury.
Sections du résumé
BACKGROUND
Thioacetamide (TAA) is used in various fields, such as synthetic drugs, organic chemical synthesis, and materials chemistry. TAA is mainly used to establish animal liver injury models and other organ damage models to explore their mechanisms for helping patients with liver disease. Liver damage can lead to abnormal expression of some enzymes in the serum, so we detected the appropriate enzyme levels in the serum of SD rats to verify the damage of TAA to the liver. More importantly, TAA caused bone damage is barely understood. Therefore, our research aims to establish a rat model reflecting the acute bone damage injury caused by TAA.
METHODS
The SD rats were intraperitoneally injected with normal saline (0.9%) or TAA (200 mg/kg, 400 mg/kg) for 1 month (once the other day). After the last intraperitoneal injection, serum samples from rats were used for biochemical tests. Masson staining is used to detect liver damage, and micro-CT is used to detect the changes in bone. Moreover, the three-point bending experiment was used to detect the force range of the hind limbs of SD rats.
RESULTS
Compared with the control group, after the intraperitoneal injection of TAA, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), total bile acid (TBA), alkaline phosphatase (ALP), carbamide (UREA) and creatinine (CREA) rose sharply, while the levels of serum content of total protein (TP), lactate dehydrogenase (LDH), calcium (Ca) and phosphorus (P) were severely reduced. After TAA administration, collagen fibers were deposited and liver fibrosis was obvious. Micro-CT results showed that the bone surface, tissue surface, bone volume, and tissue volume of rats with an intraperitoneal injection of TAA were significantly reduced. In addition, the bones of rats with an intraperitoneal injection of TAA can resist less pressure and are prone to fractures.
CONCLUSIONS
TAA can cause liver damage in SD rats, which is explained by the changes in serum biochemical indicators and the deposition of liver collagen. More importantly, TAA can reduce bone mineral density and increase the separation of bone trabeculae in SD rats, and finally lead to bone injury. This suggests that TAA may become an ideal model to investigate abnormal bone metabolism after liver injury.
Identifiants
pubmed: 35526079
doi: 10.1186/s40360-022-00568-4
pii: 10.1186/s40360-022-00568-4
pmc: PMC9080193
doi:
Substances chimiques
Thioacetamide
075T165X8M
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Informations de copyright
© 2022. The Author(s).
Références
Hepatology. 2001 Jan;33(1):301-7
pubmed: 11124849
World J Gastroenterol. 2009 Jul 7;15(25):3086-98
pubmed: 19575487
Drug Metab Dispos. 2005 Dec;33(12):1877-85
pubmed: 16183780
J Hepatol. 2005 Dec;43(6):973-83
pubmed: 16143421
Annu Rev Pharmacol Toxicol. 1982;22:321-39
pubmed: 7044288
Gut. 1986 Sep;27(9):1073-90
pubmed: 3530896
Gastroenterology. 2010 Jun;138(7):2348-56
pubmed: 20178794
N Engl J Med. 2006 Feb 16;354(7):669-83
pubmed: 16481635
Bone. 2011 May 1;48(5):1015-21
pubmed: 21352961
Front Pharmacol. 2017 Nov 01;8:791
pubmed: 29163173
Arch Toxicol. 2014 Apr;88(4):997-1006
pubmed: 24381012
Chem Res Toxicol. 2005 Apr;18(4):639-54
pubmed: 15833024
Nutr Rev. 2012 Jun;70(6):311-21
pubmed: 22646125
Science. 1948 Dec 3;108(2814):626-8
pubmed: 17783352
J Gastroenterol Hepatol. 1996 Dec;11(12):1143-54
pubmed: 9034934
Connect Tissue Res. 2018 Mar;59(2):99-107
pubmed: 28324674
Front Pharmacol. 2020 Jul 08;11:1016
pubmed: 32733249
J Hepatol. 2005 Jan;42(1):117-23
pubmed: 15629516
Anat Histol Embryol. 2000 Mar;29(1):3-8
pubmed: 10820895
Cancer Res. 1957 Nov;17(10):954-62
pubmed: 13489694
Hepatology. 2013 Dec;58(6):2070-8
pubmed: 23686738
PLoS One. 2013 Nov 28;8(11):e81652
pubmed: 24312334
Sci Rep. 2017 Jun 8;7(1):3054
pubmed: 28596526
J Neurosci Res. 2004 Feb 1;75(3):436-40
pubmed: 14743457
Toxicology. 1996 Jan 8;106(1-3):197-206
pubmed: 8571392
Acta Anat (Basel). 1984;118(2):116-21
pubmed: 6702411
J Hepatol. 2006 Feb;44(2):368-74
pubmed: 16140414
Hepatology. 1992 Jun;15(6):1099-106
pubmed: 1592350
J Hepatol. 1996 Apr;24(4):460-7
pubmed: 8738733
Acta Anat (Basel). 1986;127(4):285-9
pubmed: 3811821
Nat Biotechnol. 2012 Jan 15;30(2):179-83
pubmed: 22252509
Toxicol Appl Pharmacol. 2015 Oct 15;288(2):213-22
pubmed: 26222700
J Cell Physiol. 2019 Jun;234(6):9328-9337
pubmed: 30334569
J Surg Res. 2014 Jan;186(1):408-16
pubmed: 24071025
Nature. 1955 Feb 5;175(4449):257
pubmed: 13235865
Postgrad Med. 1978 Sep;64(3):177-82, 185
pubmed: 81485
Mutat Res. 1996 Jun 10;352(1-2):23-30
pubmed: 8676911
Dig Dis Sci. 2010 Feb;55(2):276-84
pubmed: 19242794
Rep Carcinog. 2002;10:230-1
pubmed: 15340985